B
Barret J. Rollins
Researcher at Harvard University
Publications - 3
Citations - 1009
Barret J. Rollins is an academic researcher from Harvard University. The author has contributed to research in topics: Langerhans cell histiocytosis & Histiocytoses. The author has an hindex of 3, co-authored 3 publications receiving 769 citations. Previous affiliations of Barret J. Rollins include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.
Jean-François Emile,Oussama Abla,Sylvie Fraitag,AnnaCarin Horne,Julien Haroche,Jean Donadieu,Luis Requena-Caballero,Michael B. Jordan,Omar Abdel-Wahab,Carl E. Allen,Frédéric Charlotte,Eli L. Diamond,R. Maarten Egeler,Alain Fischer,Alain Fischer,Juana Gil Herrera,Jan-Inge Henter,Filip Janku,Miriam Merad,Jennifer Picarsic,Carlos Rodriguez-Galindo,Barret J. Rollins,Barret J. Rollins,Abdellatif Tazi,Robert Vassallo,Lawrence M. Weiss +25 more
TL;DR: This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocyts and macrophage activation syndrome.
Journal ArticleDOI
Histiocytoses: emerging neoplasia behind inflammation
Julien Haroche,Fleur Cohen-Aubart,Barret J. Rollins,Jean Donadieu,Frédéric Charlotte,Ahmed Idbaih,Augusto Vaglio,Omar Abdel-Wahab,Jean-François Emile,Zahir Amoura +9 more
TL;DR: Understanding of these diseases has now evolved from the concept of a primary inflammatory condition to that of a clonal neoplastic disease, which has led to the development of effective mechanism-based therapeutic strategies for patients with histiocytic diseases.
Journal ArticleDOI
Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study
Deepak Chellapandian,Furqan Shaikh,Cor van den Bos,Gino R. Somers,Itziar Astigarraga,Rima Jubran,Barbara A. Degar,Anne Sophie Carret,Karen Mandel,Mark Belletrutti,David Dix,Johannes Visser,Nour Abuhadra,Tiffany Chang,Barret J. Rollins,James A. Whitlock,Sheila Weitzman,Oussama Abla +17 more
TL;DR: Children with Langerhans cell histiocytosis and single‐bone CNS‐risk lesions have been reported to be at increased risk of diabetes insipidus, central nervous system neurodegeneration, and recurrence of disease, but it is unknown whether the addition of chemotherapy or radiotherapy changes outcomes in these patients.